Recent performance snapshot

ACADIA Pharmaceuticals (ACAD) has been relatively stable over the past year, with a 1 year total return of 29.11%. It has also shown a modest negative move year to date and over the past month.

The stock’s past 3 months return is close to flat, and its 3 year total return of 23.07% contrasts with a 5 year total return that remains negative. This highlights a mixed longer term picture for shareholders.

With the share price at US$24.97, ACADIA Pharmaceuticals has seen a 1 year total shareholder return of 29.11%, while its shorter term share price returns point to fading momentum after earlier gains.

If this kind of move in a single biotech stock has your attention, it could be a good time to look across our screener of 30 healthcare AI stocks as potential next ideas.

With ACADIA trading at US$24.97, alongside an intrinsic value estimate that implies a discount and a gap to the average analyst price target, the key question is whether you are seeing a genuine opportunity or a market already pricing in future growth.

Most Popular Narrative: 20% Undervalued

With ACADIA Pharmaceuticals last closing at $24.97 and the most followed narrative pointing to a fair value of about $31.21, the gap between price and narrative value is clear and sets up an interesting earnings and growth story.

ACADIA's pipeline momentum with 9 disclosed programs and multiple late-stage clinical readouts expected by 2027 positions the company to significantly diversify its revenue streams, reducing risk from single-product dependence and providing potential for margin expansion as new products are launched.

Curious what kind of revenue trajectory and profit margins sit behind that fair value, and how a richer P/E assumption ties it all together? The full narrative lays out the earnings path that needs to line up for this gap between price and estimated value to make sense.

Result: Fair Value of $31.21 (UNDERVALUED)

However, this depends on ACADIA managing its reliance on NUPLAZID and avoiding major setbacks or cost pressure across its nine-program pipeline and broader R&D spending.

Next Steps

With both risks and rewards on the table, do you feel the story so far points you toward caution or opportunity, and are you ready to test that view against the underlying numbers yourself? To help you weigh those trade offs quickly and with context, take a close look at the 4 key rewards and 1 important warning sign.

Looking for more investment ideas?

If ACADIA has you thinking more broadly about your portfolio, do not stop here. Use this momentum to size up other opportunities before the crowd does.

• Spot potential value with 53 high quality undervalued stocks that combine solid fundamentals with prices that may not fully reflect their current financial profile.
• Strengthen your income stream by reviewing 15 dividend fortresses that offer higher yields while still focusing on financial resilience.
• Reduce portfolio stress by scanning 80 resilient stocks with low risk scores that score well on stability so short term swings feel more manageable.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.